Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy†
Article first published online: 4 FEB 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Volume 49, Issue 5, pages 1503–1514, May 2009
How to Cite
Tenney, D. J., Rose, R. E., Baldick, C. J., Pokornowski, K. A., Eggers, B. J., Fang, J., Wichroski, M. J., Xu, D., Yang, J., Wilber, R. B. and Colonno, R. J. (2009), Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology, 49: 1503–1514. doi: 10.1002/hep.22841
Potential conflict of interest: The studies were performed at Bristol-Myers Squibb by employees of Bristol-Myers Squibb. Study participants have been informed of potential conflicts of interest.Drs. Wilber, Eggers, Colonno, Baldick, Tenney, Pokornowski, and Xu own stocks in Bristol-Myers Squibb.
- Issue published online: 27 APR 2009
- Article first published online: 4 FEB 2009
- Accepted manuscript online: 4 FEB 2009 12:00AM EST
- Manuscript Accepted: 25 DEC 2008
- Manuscript Received: 20 AUG 2008
- 6Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. [Abstract] HEPATOLOGY 2006; 44: 222A., , , , , , et al.
- 12Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 24 wk results (E.A.R.L.Y. Study). [Abstract] HEPATOLOGY 2006; 44 (4 Suppl. 1): 554A., , , , , et al.
- 17Three year assessment of entecavir (ETV) resistance in nucleoside-naive and lamivudine (LVD) refractory Japanese patients with chronic hepatitis B (CHB). Hepatol Int 2008; 2: A161(Abstract FP067)., , , , , , et al.
- 29Assessment at three years shows high barrier to resistance is maintained in entecavir treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. [Abstract] HEPATOLOGY 2006; 44: 229A., , , , , .
- 35Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic resistance and virologic rebound. HEPATOLOGY 2006; 44 (4 Suppl. 1): 253A–254A., , , , , , et al.